FDA Chases Another Synthetic Stimulant Off Supplement Ingredient Menu
This article was originally published in The Tan Sheet
Executive Summary
CFSAN tells 14 firms the stimulant DMBA – identified by names including 1,3-dimethylbutylamine, 2-amino-4-methylpentane, AMP citrate and 4-methyl-2-pentanamine – has “no history of use or other evidence of safety … when used as a dietary ingredient.”
You may also be interested in...
Kirkman Acquires Rose, IQ Recalls Picamilon Supplement: Health And Wellness Industry News Roundup
Recalls reported by FDA for health and wellness products.
Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”
Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.
US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector
"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: